Although the CRC patients with high FSTL3 expression may be indicated for ICB treatment due to the characteristics of MSI-H, their high levels of IDO1 expression and Tregs infiltration result in ICB resistance. This evidence concerns the gene IDO1 and colorectal carcinoma.